Bonesupport Holding AB (publ) (0RQO.L) LSE
242.25
-12.47492(-4.90%)
Currency In SEK
- General
- Statistics
- Historical Data
- Profile
- Financials
242.25
-12.47492(-4.90%)
Currency In SEK
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
140
First IPO Date
December 14, 2017
| Name | Title | Pay | Year Born |
| Torbjorn Skold | Chief Executive Officer | 14.37M | 1977 |
| Håkan Johansson | Chief Financial Officer | 3.01M | 1963 |
| Michael Diefenbeck | Executive Vice President of Medical & Clinical Affairs and Chief Medical Officer | 0 | 1974 |
| Fergus MacLeod | GM & Executive VP of Commercial Operations of EUROW | 0 | 1970 |
| Michael Roth | GM & Executive Vice President of Commercial Operations of North America | 0 | 1963 |
| Michael Wrang Mortensen | Executive Vice President of Global R&D and Operations | 0 | 1975 |
| Anna Stegmark | Executive Vice President of Quality Management & Regulatory Affairs | 0 | 1980 |
| Annelie Aava Vikner | Executive Vice President of Global Marketing | 0 | 1971 |
| Helena L. Brandt | Executive Vice President of Human Resources | 0 | 1965 |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.